These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049 [TBL] [Abstract][Full Text] [Related]
12. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945 [No Abstract] [Full Text] [Related]
13. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109 [TBL] [Abstract][Full Text] [Related]
14. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073 [TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa: Evaluation of Pathogen Burden and Drug-Resistance Trends in a Tertiary Care Hospital. Saeed M; Rasheed F; Afzal RK; Hussain S; Riaz S; Ahmad A J Coll Physicians Surg Pak; 2018 Apr; 28(4):279-283. PubMed ID: 29615167 [TBL] [Abstract][Full Text] [Related]
16. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model. Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072 [TBL] [Abstract][Full Text] [Related]
18. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa]. Pinilla-Rello A; Huarte-Lacunza R; Magallón-Martínez A; Cazorla-Poderoso L; Pereira-Blanco O; Pérez-Moreno M; Larrodé-Leciñena I; Martínez-Álvarez RM; López-Calleja AI Rev Esp Quimioter; 2021 Oct; 34(5):441-449. PubMed ID: 34154319 [TBL] [Abstract][Full Text] [Related]
19. Antibiotic resistance of Pseudomonas aeruginosa isolated from hospital wastewater in the Czech Republic. Roulová N; Mot'ková P; Brožková I; Pejchalová M J Water Health; 2022 Apr; 20(4):692-701. PubMed ID: 35482385 [TBL] [Abstract][Full Text] [Related]
20. Genomics of Aminoglycoside Resistance in Pseudomonas aeruginosa Bloodstream Infections at a United States Academic Hospital. Atassi G; Medernach R; Scheetz M; Nozick S; Rhodes NJ; Murphy-Belcaster M; Murphy KR; Alisoltani A; Ozer EA; Hauser AR Microbiol Spectr; 2023 Jun; 11(3):e0508722. PubMed ID: 37191517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]